ID: ALA2030367

Max Phase: Preclinical

Molecular Formula: C16H23FN4O3

Molecular Weight: 338.38

Molecule Type: Small molecule

Representations

Canonical SMILES:  NC(=O)c1c(N)nc(OC2CCCC2)nc1OC1CCCCC1F

Standard InChI:  InChI=1S/C16H23FN4O3/c17-10-7-3-4-8-11(10)24-15-12(14(19)22)13(18)20-16(21-15)23-9-5-1-2-6-9/h9-11H,1-8H2,(H2,19,22)(H2,18,20,21)

Standard InChI Key:  RZOBFPPQBGMJTQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 338.38

Molecular Weight (Monoisotopic): 338.1754

AlogP: 2.14

#Rotatable Bonds: 5

Polar Surface Area: 113.35

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.41

CX Basic pKa: 3.87

CX LogP: 3.24

CX LogD: 3.24

Aromatic Rings: 1

Heavy Atoms: 24

QED Weighted: 0.85

Np Likeness Score: -0.16

References

1. Gu W, Wang T, Maltais F, Ledford B, Kennedy J, Wei Y, Gross CH, Parsons J, Duncan L, Arends SJ, Moody C, Perola E, Green J, Charifson PS..  (2012)  Design, synthesis and biological evaluation of potent NAD+-dependent DNA ligase inhibitors as potential antibacterial agents. Part I: aminoalkoxypyrimidine carboxamides.,  22  (11): [PMID:22560473] [10.1016/j.bmcl.2012.04.037]

Source

Source(1):

• Scientific Literature